Zenas BioPharma completes $225M IPO to fund biopharmaceutical development and commercialization.

Zenas BioPharma has successfully priced its upsized initial public offering (IPO), raising $225 million. This funding aims to support the company's ongoing development and commercialization efforts in the biopharmaceutical sector. The IPO reflects strong investor interest and positions Zenas for future growth in the competitive market.

September 13, 2024
8 Articles

Further Reading